These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25601769)

  • 1. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease.
    Hirohata S; Kikuchi H; Sawada T; Nagafuchi H; Kuwana M; Takeno M; Ishigatsubo Y
    J Neurol Sci; 2015 Feb; 349(1-2):143-8. PubMed ID: 25601769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of neurological manifestations of Behçet's disease: a retrospective monocentric study in Tunisia.
    Houman MH; Bellakhal S; Ben Salem T; Hamzaoui A; Braham A; Lamloum M; Monia SK; Ben Ghorbel I
    Clin Neurol Neurosurg; 2013 Oct; 115(10):2015-8. PubMed ID: 23830180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuro-behçet's disease in South Korea: clinical characteristics and treatment response.
    Yoon DL; Kim YJ; Koo BS; Kim YG; Lee CK; Yoo B
    Int J Rheum Dis; 2014 May; 17(4):453-8. PubMed ID: 24506839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological manifestations of Behçet's disease: evaluation of 40 patients treated by cyclophosphamide.
    Ait Ben Haddou EH; Imounan F; Regragui W; Mouti O; Benchakroune N; Abouqal R; Benomar A; Yahyaoui M
    Rev Neurol (Paris); 2012 Apr; 168(4):344-9. PubMed ID: 22136880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose MTX for progressive neuro-Behçet's disease. A follow-up study for 4 years.
    Kikuchi H; Aramaki K; Hirohata S
    Adv Exp Med Biol; 2003; 528():575-8. PubMed ID: 12918768
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recent aspects of Neuro-Behcet's disease].
    Hirohata S
    Brain Nerve; 2013 Nov; 65(11):1245-53. PubMed ID: 24200602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical observation of 85 patients with Behçet's uveitis treated with immunosuppressive agents combined with steroids].
    Zhao M; Wang H; Jiao X; Wei WB
    Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):202-6. PubMed ID: 23866699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Width of the third ventricle as a highly-sensitive biomarker in chronic progressive neuro-Behçet's disease.
    Takahashi S; Sanjo N; Miyamoto S; Hattori T; Oyama J; Tateishi U; Yokota T
    J Neurol Sci; 2021 Feb; 421():117284. PubMed ID: 33360732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain stem and cerebellar atrophy in chronic progressive neuro-Behçet's disease.
    Kanoto M; Hosoya T; Toyoguchi Y; Oda A
    Eur J Radiol; 2013 Jan; 82(1):146-50. PubMed ID: 23083524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience.
    Bolek EC; Sari A; Kilic L; Kalyoncu U; Kurne A; Oguz KK; Topcuoglu MA; Ertenli I; Karadag O
    Mult Scler Relat Disord; 2020 Feb; 38():101512. PubMed ID: 31733425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of various factors on the relapse of acute neurological attacks in Behçet's disease.
    Hirohata S; Kikuchi H; Sawada T; Nagafuchi H; Kuwana M; Takeno M; Ishigatsubo Y
    Mod Rheumatol; 2014 Nov; 24(6):961-5. PubMed ID: 24645723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Low-dose weekly methotrexate therapy for progressive neuro-Behçet's disease].
    Suda H
    Nihon Rinsho Meneki Gakkai Kaishi; 1999 Feb; 22(1):13-22. PubMed ID: 11185687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Central nervous system involvement in Behçet's disease].
    Hirohata S
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1147-9. PubMed ID: 12235822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Clinical Features and Risk Factors of Parenchymal Neuro-Behcet's Disease.
    Yan D; Liu J; Zhang Y; Yuan W; Xu Y; Shi J; Li C; Wang Y; Peng L; Yang Y; Zhou J; Wu D; Liu Z; Zeng X; Zhang F; Zheng W; Zhao Y
    J Immunol Res; 2019; 2019():7371458. PubMed ID: 31612152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging findings and outcome of neuro-Behçet's disease: the predictive factors.
    Farahangiz S; Sarhadi S; Safari A; Borhani-Haghighi A
    Int J Rheum Dis; 2012 Dec; 15(6):e142-9. PubMed ID: 23253242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease.
    Hirohata S; Suda H; Hashimoto T
    J Neurol Sci; 1998 Aug; 159(2):181-5. PubMed ID: 9741405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuro-Behçet's disease mimicking a cranial tumour.
    Senol S; Ucar M; İmamoğlu H; Yildirim A
    BMJ Case Rep; 2015 Jun; 2015():. PubMed ID: 26101297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of neuro-Behçet's disease.
    Noel N; Bernard R; Wechsler B; Resche-Rigon M; Depaz R; Le Thi Huong Boutin D; Piette JC; Drier A; Dormont D; Cacoub P; Saadoun D
    Arthritis Rheumatol; 2014 May; 66(5):1306-14. PubMed ID: 24782188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years.
    Davatchi F; Sadeghi Abdollahi B; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Faezi T; Akhlaghi M; Ghodsi Z; Ashofteh F; Mohtasham N
    Int J Rheum Dis; 2014 May; 17(4):444-52. PubMed ID: 24314325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years.
    Davatchi F; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Sadeghi Abdollahi B; Faezi T; Akhlaghi M; Ashofteh F
    Int J Rheum Dis; 2013 Oct; 16(5):568-77. PubMed ID: 24164845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.